ArticleJournal of pharmaceutical policy and practice2024

Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway.

Mahnum Shahzad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.